I got an ambulance ride, CT scan and ER care in Brazil. My bill: $0.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
28 minutes ago
- CNN
‘Good moral character,' too many tourists, the latest K-pop hit: Catch up on the day's stories
👋 Welcome to 5 Things PM! When kids head back to school, there's a good chance they will use AI to help with their homework. It's important for parents to talk to them about when they should — and shouldn't — do so. An expert offered some tips. Here's what else you might have missed during your busy day. The Trump administration is expanding the requirement for immigrants who are hoping to become US citizens to display 'good moral character.' Some immigration lawyers called it a troubling change that adds uncertainty to the naturalization process. This has been Europe's summer of discontent, with locals protesting overtourism everywhere from Tenerife to the Louvre. As destinations take action to stem the not-so-subtle anger, what does the future hold for mass tourism? The end could be near for Spirit Airlines, which recently said there was 'substantial doubt' it could stay in business for more than a year. That would be bad news not just for employees and customers but for everyone seeking bargain airfares. Financial scams are nothing new, but the internet, social media, AI and crypto make it so much easier for the bad guys these days. There are telltale signs that something is fishy — and ways to reduce your chances of being swindled. Netflix has a hit on its hands with 'KPop Demon Hunters,' which debuted in June and is on track to become the platform's most-watched original film. Here's why the animated flick is slaying summer. GET '5 THINGS' IN YOUR INBOX If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter.⛪ Church on wheels: The Kiruna Church was previously named Sweden's most beautiful building. It's now part of a project that will relocate nearly 6,000 residents and some of Kiruna's buildings. See how they tackled this massive move. Hurricane Erin is stirring up nearly 30-foot waves well offshore as it continues north Trump is pressuring yet another top Fed official to resign Judge rejects Trump administration request to release Jeffrey Epstein grand jury documents 💧H2-whoa: Ever feel like the boring one at the table when you don't order alcohol? Well, fear not — this British restaurant has your back after launching the UK's first water menu. 🇷🇺 What gift did the Russian government give an Alaska man after last week's high-stakes summit between President Donald Trump and President Vladimir Putin? A. A stuffed brown bearB. A motorcycleC. A pair of binocularsD. $10,000⬇️ Scroll down for the answer. 👋 We'll see you tomorrow.🏍️ Quiz answer: B. Mark Warren, a retired fire inspector from Anchorage, received a motorcycle after his interview went viral in Russia.📧 Check out all of CNN's newsletters. Today's edition of 5 Things PM was edited and produced by CNN's Kimberly Richardson and Meghan Pryce.
Yahoo
an hour ago
- Yahoo
Penumbra, Inc. to Present at Upcoming Investor Conferences
ALAMEDA, Calif., Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45am ET/5:45am PT Event: Morgan Stanley 23rd Annual Global Healthcare Conference Date: Tuesday, September 9, 2025 Time: 1:50pm ET/10:50am PT Webcasts of the presentations can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at The webcasts will be available on the company's website for at least two weeks following each event. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit and connect on Instagram, LinkedIn and X. Investor RelationsPenumbra, View original content to download multimedia: SOURCE Penumbra, Inc. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Exclusive-CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said. Current HIV prevention recommendations from the U.S. Preventive Services Task Force (USPSTF), which is supported by HHS, include only three older drugs. A source familiar with the situation suggested that Gilead is still negotiating with CVS over Yeztugo, a twice-yearly injection with a U.S. list price of more than $28,000 a year. The decision by CVS is "a grave disappointment and frankly a missed opportunity," said Mitchell Warren, executive director of the AIDS nonprofit AVAC. "It does reflect a price that is too high and a U.S. pharmaceutical pricing structure that is frankly not sustainable." He and other AIDS activists have said Yeztugo could be a transformative tool in ending the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. Pharmacy benefit managers, or PBMs, act as middlemen between drug companies and consumers. They negotiate volume discounts with drug manufacturers on behalf of employers and health plans based on coverage terms. The three largest - CVS Caremark, UnitedHealth Group's OptumRX and Cigna's Express Scripts - control about 70% of specialty drug prescriptions in the U.S. Optum said Yeztugo will be reviewed for coverage in the coming weeks, while Express Scripts did not respond to requests for comment. Gilead, which declined to comment, said earlier this month it is on track to secure 75% U.S. insurer coverage of Yeztugo by year-end and 90% coverage by June 2026. Its CEO, Daniel O'Day, has said that half of every dollar spent on medicines in the U.S. goes to PBMs and other entities that do not make drugs. U.S. government healthcare programs, including the Veterans Administration and the Medicare program for people over age 65, have already added Yeztugo to coverage lists. Gilead said earlier this month that several state-run Medicaid plans, including California and New York, were covering the drug. Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the drug was shown to be nearly 100% effective at preventing infection in large trials, fueling fresh optimism about limiting the spread of HIV. Some analysts have warned that a recent Supreme Court ruling affirming broad HHS authority over the USPSTF could affect coverage prospects while Robert F. Kennedy Jr is in charge of the agency. Medical groups have expressed alarm about reports that Kennedy could replace members of the task force. The 16-member task force reviews evidence and public input, then recommends preventive services that catch disease early or prevent worsening, which insurers must cover without patient cost-sharing. For HIV prevention, it endorses daily PrEP pills Truvada, which is available as a generic, and Gilead's Descovy, as well as ViiV Healthcare's bimonthly shot Apretude. Gilead's O'Day has stressed that the lifetime cost of treating an HIV patient can exceed $1 million, making a preventive treatment cost effective. (Reporting By Deena Beasley; Editing by Patrick Wingrove and Diane Craft) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
